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WOMACAbstract Aim of the work: The aim of this study was to investigate plasma basic ﬁbroblast growth
factor (bFGF) levels in patients with primary knee osteoarthritis (KOA) and to correlate it with
physical performance, functional status and radiological severity.
Patients and methods: Sixty patients with primary KOA and 30 healthy individuals were
recruited into this study. Measures of physical performance were assessed using Chair Stand Test,
Stair Climb Test and Six-Minute Walk Test. Functional assessment was carried out using the Wes-
tern Ontario and McMaster Universities (WOMAC) index. KOA severity was determined using X-
ray evaluated according to the Kellgren–Lawrence (KL) grading and all underwent sonographic
examination. bFGF concentrations in plasma were determined.
Results: The mean age of the KOA patients was 53.67 ± 7.99 years, female:male 4:1 and disease
duration of 4.17 ± 1.74 years. KOA was bilateral in 71.7% and knee effusion was present in
20.39%. The WOMAC index was 53.78 ± 13.7. Plasma bFGF levels in KOA patients (43.82
± 20.18 pg/ml) were signiﬁcantly higher than in controls (12.40 ± 9.12 pg/ml) (p< 0.001). bFGF
signiﬁcantly correlated the KL radiographic grading (r= 0.31, p< 0.027) and negatively with car-
tilage thickness of medial and lateral femoral condyles (r= 0.38, p< 0.006).
Conclusions: Plasma bFGF levels were signiﬁcantly increased in OA patients, and these elevated
levels were signiﬁcantly correlated with the degree of radiographic severity evaluated by KL grading
scale and cartilage degeneration evaluated by ultrasound. These ﬁndings indicate that bFGF levels
may be a monitor of disease severity and could play an essential part in the pathophysiology of
degenerative process in OA.
 2016 Egyptian Society for JointDiseases andArthritis. Production and hosting byElsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).e Egyp-
2 A.E. El-Fetiany et al.1. Introduction
Osteoarthritis (OA) is a common chronic disease that affects
all joint tissues, causing progressive irreversible damage.
Pathological changes in OA not only include joint cartilage
degeneration but also subchondral bone thickening, osteo-
phyte formation and synovial inﬂammation, all of which are
associated with capsule laxity and decreased muscle strength
[1].
Many factors have been implicated in the pathogenesis of
Egyptian patients with Knee OA (KOA) as interleukin-1b,
tumor necrosis factor-a, leptin, matrix metalloproteinase,
nitric oxide [2] hyaluronic acid, cartilage oligomeric cartilage
protein [3,4], and oxidative stress [5]. Vascular endothelial
growth factor signiﬁcantly correlated with clinical manifesta-
tions, functional impact, as well as radiological changes of
KOA [6]. Osteopontin was found to serve as another biomar-
ker of disease severity in KOA and could be predictive to the
progression of the disease [7] and with radiological grading [8].
Osteoarthritis patients are frequently associated with subclini-
cal atherosclerosis [9] and obese KOA patients were found to
represent a high risk group for renal dysfunction [10].
Basic ﬁbroblast growth factor (bFGF), also known as
FGF-2, is a polypeptide with pleiotropic effects when applied
to diverse tissues, including mitogenesis, cell migration and cell
differentiation [11]. FGF-2 plays an important role in tissue
repair and angiogenesis. It is responsible for wound healing
and modulates many cellular functions, including prolifera-
tion, differentiation and neovascularization [12,13]. However,
in systemic sclerosis, another rheumatic disease, the serum
level of FGF-23 showed no signiﬁcant difference between
patients and normal subjects with no role in the clinical man-
ifestations of the disease [14].
Ultrasound (US) imaging is a non-invasive technique that
can be used to image soft tissues. With the advancement of
technology, the newer US machine models can be equipped
with high frequency probes that are very useful for muscu-
loskeletal imaging to study the peri-articular and intra-
articular structures [15,16].
The aim of this study was to investigate plasma basic
ﬁbroblast growth factor (bFGF) levels in patients with pri-
mary knee osteoarthritis and to evaluate the correlation
between it and clinical and radiographic parameters including
conventional X-ray and ultrasonography.
2. Patients and methods
Sixty patients with primary KOA selected from the outpatient
clinic of Physical Medicine, Rheumatology and Rehabilitation
Department, Tanta University Hospitals. Patients fulﬁlled the
criteria of the American College of Rheumatology (ACR) [17]
for diagnosis of osteoarthritis knee. Thirty healthy volunteers
matched in age, sex and body mass index (BMI) were selected
as controls. The study was approved by the local research
ethics committee of Faculty of Medicine, Tanta University
and the patients gave an informed consent before being
enrolled. Patients with other forms of arthritis, chronic inﬂam-
matory diseases, diabetes, cancer and patients with past history
of knee trauma or corticosteroid injection within the past three
months were excluded from the study.Please cite this article in press as: El-Fetiany AE et al. Evaluation of plasma basic fibr
tian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.03.006The following were clinically assessed for the patients: BMI,
pain using Visual Analogue Scale (VAS) [18], and duration of
morning stiffness and knee effusion. Measures of physical per-
formance were assessed using Chair Stand Test (CST), Stair
Climb Test (SCT) and Six-Minute Walk Test (6MWT) [19].
Functional assessment was carried out using the WOMAC
(Western Ontario and McMaster Universities) index [20].
Venous blood samples were collected from all participants
with sterile disposable syringes in sterile EDTA vacuum tube,
and samples were centrifuged at 1000g for 15 min for plasma
separation by means of dry clean Pasteur pipette. The plasma
samples were frozen at 70 C until used for assay of plasma
basic ﬁbroblast growth factor (bFGF) level byELISA technique
[21]. (Quantikine ELISA Human FGF basic Immunoassay kit
Catalog Number DFB50 supplied by Clini Lab Scientiﬁc Ser-
vice Company).
Osteoarthritis severity was determined using weight-bearing
anteroposterior and lateral radiographs of the affected knee
and was evaluated according to the Kellgren Lawrence (KL)
grading system [22]. All the patients underwent sonographic
examination at ultrasound unit of Physical Medicine,
Rheumatology and Rehabilitation Department of Tanta
University Educational Hospital using SAMSUNG MEDI-
SON (UGEO H60) by an expert radiologist blinded to the clin-
ical and radiological data, using linear array transducers (with
frequencies ranging between 7.5 and 12 MHz). Power Colour
Doppler was used to check for blood ﬂow in the synovium.
The following were considered during the ultrasound assess-
ment: supra-patella recess effusion (mm), synovitis, synovial
thickness (mm), cartilage thickness at medial and lateral
femoral condyles (maximal and minimal thickness in mm),
medical and lateral menisci (positive or negative degeneration)
and presence of osteophytes [23].
2.1. Statistical analysis
Statistical analysis was carried out using the SPSS software,
version 16.0. Demographic data between patients and controls
were compared by chi-square tests and unpaired Student’s t
tests where appropriate. Pearson’s correlation coefﬁcient (r)
was employed to determine correlation between concentrations
of bFGF in plasma and clinical and radiographic parameters.
Data are expressed as mean ± standard deviation (SD). p val-
ues <0.05 were considered statistically signiﬁcant for differ-
ences and correlation.
3. Results
Sixty knee OA patients and thirty healthy controls were
enrolled in this study. There was no signiﬁcant difference in
demographic data between OA patients and controls. How-
ever, there was a signiﬁcant difference between OA patients
and controls regarding physical performance assessments and
plasma bFGF levels as demonstrated in Table 1.
Regarding KL criteria; 35.9% and 32% of KOA patients
revealed KL grades 1 and 3 respectively, while 25.3% and
6.8% revealed grades 2 and 4 respectively. Ultrasound ﬁndings
in OA patients were demonstrated in Table 2. The decreased
cartilage thickness of medial and lateral femoral condyle in
knee osteoarthritis patient is shown in Fig. 1.oblast growth factor (bFGF) in primary knee osteoarthritis patients, The Egyp-
Table 1 Demographic, clinical and laboratory data in knee
osteoarthritis patients and controls.
Mean ± SD or n
(%)
KOA patients
(n= 60)
Control
(n= 30)
p-value
Age (years) 53.67 ± 7.99 51.53
± 4.46
0.11
Sex (female/male) 48/12 20/10 0.17
BMI 33.94 ± 7.07 32.67
± 2.48
0.22
Disease duration
(years)
4.17 ± 1.74 –
Bilateral 43 (71.7)
Unilateral 17 (28.3)
VAS 6.53 ± 1.56 –
Morning stiﬀness
(min.)
7.42 ± 5.78 –
Knee eﬀusion 21(20.39) –
WOMAC index 53.78 ± 13.7 –
CST (times/30 s) 5.65 ± 1.72 11.07
± 0.78
<0.001*
SCT (/s) 12.98 ± 6.37 6.47 ± 1.01 <0.001*
6MWT (/m) 93.5 ± 22.16 187.33
± 37.5
<0.001*
Plasma bFGF level
(pg/ml)
43.82 ± 20.18 12.40
± 9.12
<0.001*
KOA: knee osteoarthritis; BMI: body mass index; VAS: Visual
Analogue Scale; WOMAC: Western Ontario and McMaster
Universities; CST: Chair Stand Test; 6MWT: Six-Minute Walk
Test, SCT: Stair Climb Test; bFGF: basic ﬁbroblast growth factor.
* Signiﬁcantly different at p< 0.05.
Table 2 Ultrasound ﬁndings in the knees of knee osteoarthri-
tis patients.
Ultrasound ﬁndings KOA patients (n = 60)
n (%) – mean ± SD Findings in 103 knees
Eﬀusion (ml) 25 (24.3)
0.61 ± 0.85
Synovial thickening (mm) 24 (23.3)
3.92 ± 2.48
Synovial activity 0
Osteophytes 66 (64.08)
Meniscal degeneration 4 (3.88)
Cartilage thickness (mm)
Medial femoral condyle
Minimal 1.16 ± 0.59
Maximum 1.72 ± 0.77
Lateral femoral condyle
Minimal 1.41 ± 0.58
Maximum 2.15 ± 0.52
KOA: knee osteoarthritis.
Evaluation of plasma basic ﬁbroblast growth factor 3Plasma bFGF level signiﬁcantly correlated with the KL
radiographic grading of KOA (r= 0.31, p= 0.027) (Fig. 2).
In additions, plasma bFGF levels negatively correlated with
cartilage thickness of medial and lateral femoral condyles mea-
sured by ultrasonography. (r= 0.38, p= 0.006) (Table 3).
However, there was no signiﬁcant correlation between plasma
bFGF levels and other sonographic ﬁndings. Moreover, noPlease cite this article in press as: El-Fetiany AE et al. Evaluation of plasma basic fibr
tian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.03.006signiﬁcant correlation was found between plasma bFGF levels
and clinical data and physical performance.
4. Discussion
Knee osteoarthritis was more frequent in females in the present
study. In another study on Egyptian patients with primary
KOA, females were signiﬁcantly more involved [2].
Fibroblast growth factors (FGFs) represent a large
cytokine family of structurally related multifunctional
polypeptide mitogens of widespread tissue distribution.[24]
Basic FGF is one of the most well-characterized members of
the family and one of the most powerful angiogenic polypep-
tides [25].
Our study demonstrated that the plasma basic ﬁbroblast
growth factor (bFGF) levels in OA patients were signiﬁcantly
higher than the control group. These results were in agreement
with, Honsawek et al. [26] who measured plasma and synovial
bFGF levels in thirty-ﬁve patients with primary KOA and
found that their levels were signiﬁcantly elevated compared
with that of healthy controls. Jingushi et al. [27] showed that
when radiolabeled FGF-2 was injected into knee joints of
C57Bl/10 mice, a transient binding was observed in the super-
ﬁcial and intermediate zones of the articular cartilage as well as
in the synovium and perichondrium. FGF-2 injection (5 lg)
caused synovial hyperplasia adjacent to the articular cartilage
on day 7, cartilage formation adjacent to the articular cartilage
on day 14, and osteophyte on day 21. These changes were
dose-dependent. No destructive changes in the joints were
observed. Im et al. [28] documented that FGF-2 induces
matrix metalloproteinase-13 (MMP-13), the most potent
collagen-type II degrading enzyme in human articular carti-
lage, resulting in collagen breakdown. They used chondrocytes
isolated from human adult articular cartilage 24 h after death.
Treatment of cells in monolayer with bFGF signiﬁcantly stim-
ulated MMP-13 production, and the induction occurred in
both mRNA and protein levels in a dose-dependent manner.
bFGF stimulates MMP-13 via molecular cross-talk between
mitogen-activated protein kinases and protein kinase C delta
pathways in articular chondrocytes. Li et al. [29] provide a bio-
chemical explanation for the conﬂicting effects induced by
FGF-2 on articular cartilage human and mice, using human
articular cartilage (ex vivo) and a medial meniscal destabiliza-
tion animal model (in vivo). The differences in the expression
patterns of FGFR receptors (FGFRs) explain these conﬂicting
effects. In normal human cartilage, FGFR1 and FGFR3 are
predominantly expressed, with negligible levels of FGFR2
and FGFR4. In OA cartilage, FGFR3 expression level is
markedly reduced, and this is closely linked with enhanced
catabolic signaling in the presence of FGF-2. FGF-2 highly
up regulates FGFR3 in murine chondrocytes, whereas FGF-
2 signiﬁcantly down regulates FGFR3 in human articular
chondrocytes. Thus, in mice, FGFR3 may also play an ana-
bolic role in articular cartilage after injection with FGF-2.
The WOMAC index was used for functional assessment of
the present KOA patients and a non-signiﬁcant correlation
was found with the plasma bFGF levels. The severity of KOA
in our patients was detected by KL grading and ultrasonogra-
phy of knee joint to assess cartilage thickness, effusion, synovial
thickening and meniscal degeneration. KL grades 1, 2, 3 and 4
were found in 35.9%, 25.3%, 32% and 6.8%. The US revealedoblast growth factor (bFGF) in primary knee osteoarthritis patients, The Egyp-
Figure 1 Decreased cartilage thickness of medial (left) and lateral (right) femoral condyle in knee osteoarthritis (KOA) patients.
Figure 2 Correlation between plasma bFGF levels and KL
grades in KOA patients (n= 60; 103 knees).
Table 3 Correlation between plasma bFGF levels and ultra-
sound (US) ﬁndings in KOA.
KOA patients (n= 60) OA knee (n= 103)
US readings r (p) Plasma bFGF (pg/ml)
Eﬀusion (ml) 0.12 (0.39)
Synovial thickening (mm) 0.15 (0.29)
Cartilage thickness (mm)
Medial femoral condyle
Minimal 0.38 (0.006)*
Maximum 0.38 (0.006)*
Lateral femoral condyle
Minimal 0.38 (0.006)*
Maximum 0.3 (0.03)*
KOA: knee osteoarthritis; US: ultrasound, bFGF: basic ﬁbroblast
growth factor.
* Signiﬁcant at p< 0.05.
4 A.E. El-Fetiany et al.effusion in 24.3%, synovial thickening in 23.3%, osteophytes in
64.08% and meniscal degeneration in 3.88%. The cartilage
thickness was more reduced over the medial condyle.Please cite this article in press as: El-Fetiany AE et al. Evaluation of plasma basic fibr
tian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.03.006Saarakkala, et al. [30] investigated the diagnostic perfor-
mance of non-invasive knee US to detect degenerative changes
of articular cartilage compared to arthroscopic grading as the
gold standard. They concluded that the sum of cartilage grades
signiﬁcantly correlated between both modalities and that knee
US is a promising technique for screening but a negative ﬁnd-
ing does not rule out degenerative changes of articular
cartilage.
Our study found that plasma bFGF levels signiﬁcantly cor-
related with KL grades of OA knees and negatively with carti-
lage thickness of both medial and lateral femoral condyles in
OA knees detected by US. This was in agreement with Hon-
sawek et al. [26] who found that plasma and synovial bFGF
levels were signiﬁcantly increased in OA patients and corre-
lated with radiographic severity using KL grading. They
observed that plasma bFGF levels were more pronounced in
end-stage compared with early OA patients. The correlation
of plasma bFGF levels with OA severity was explained by Li
et al. [29] who documented that bFGF plays a catabolic and
anti-anabolic role in cartilage homeostasis, driving homeosta-
sis toward degeneration.
In conclusion, the study revealed that plasma bFGF in
patients with primary knee OA was signiﬁcantly elevated com-
pared with that of healthy controls. Plasma bFGF levels signif-
icantly correlated with the degree of radiographic severity
evaluated by KL grading scale and negatively with cartilage
thickness of both medial and lateral femoral condyles. These
ﬁndings suggest that bFGF could be a useful biochemical
parameter to reﬂect disease severity in KOA. Further studies
are needed to explore the role of bFGF in the pathogenesis
and progression of primary KOA and the possibility of being
a novel therapeutic target.
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